Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 5,141 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: HIV-1-infection
Interventions: B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 66
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more

Conditions: HIV, Endothelial Dysfunction, Oxidative Stress
Interventions: PharmaNAC (N-acetylcysteine), Matching placebo; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HIV Infections
Interventions: Celgosivir hydrochloride; Drug
Lead sponsor: Hoechst Marion Roussel; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 24
States / cities: Mobile, Alabama • Beverly Hills, California • Los Angeles, California + 20 more

Conditions: HIV Infections, Coronary Atherosclerosis
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Antibodies
Interventions: VRC-HIVMAB091-00-AB, rHuPH20; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Disease
Interventions: Efavirenz, Rilpivirine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Antivirals/HIV
Interventions: Rifabutin, Rifabutin + Atazanavir + Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: HIV Infections
Interventions: Quadrivalent HPV Vaccine, Placebo Vaccine for Male Participants Only, Placebo Vaccine for Female Participants Only; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 27 Years and older
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: HIV Infections
Interventions: VRC07-523LS, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: AIDS/HIV
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: University of Massachusetts, Boston; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Attention Deficit Disorder With Hyperactivity, HIV Infections, Paralysis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hiv, Diabetes Mellitus, Type 2
Interventions: Subcutaneous adipose tissue biopsy, CT scan, Oral glucose tolerance test, Blood collection; Procedure · Radiation · Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mental Health Issue, Hiv, Substance Use
Interventions: Single Session Narrative Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Human Immunodeficiency Virus Transmission
Interventions: PC4PrEP- Intervention Clinics, Standard of Care Clinics; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV
Interventions: Group-Based Social Support, HIV Stigma Reduction, Strengths-Based Case Management (SBCM), Personalized Technology Detailing; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 50 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Clinician Attitudes About PrEP
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Honolulu, Hawaii + 4 more

Conditions: Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study; Biological · Drug · Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Cysteamine, Zidovudine; Drug
Lead sponsor: Mylan Laboratories; Industry
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Tampa, Florida • New Orleans, Louisiana • Stony Brook, New York + 3 more

Conditions: High Risk MSM, HIV Negative, 18-30 Years of Age
Interventions: HEC Placebo Gel, Tenofovir 1% Gel; Other · Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: HIV Infection
Interventions: Pegylated Interferon Alpha 2b (PEGINTRON); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: HIV, Hepatitis
Interventions: Intervention Condition, Control Condition; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,024 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Foster City, California

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 38
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 28 more

Search by objective public record fields.

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

Subclinical Atherosclerosis in HIV-infected Patients

Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

Drug Interaction Study

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

Smoking Cessation Intervention for Women Living With HIV

Assessment of Attentional Functioning in Children With HIV-1 Infection

The HIV, Adipose Tissue Immunology, and Metabolism Study

Walk-in Therapy in Low Barrier Primary Care

PC4PrEP: Integrating PrEP Into Primary Care

Multi-Component Intervention to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV

Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention

Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease

Microbicide Safety and Acceptability in Young Men

Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy

A Network & Dyad HIV Prevention Intervention for IDU's - 1

Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome